The first phase of testing of the Lina M cancer drug has begun in the Russian Federation

An oncological drug developed by the pharmaceutical company Lina M has begun to undergo the first phase of clinical trials out of three required by law, so it is too early to judge its effectiveness, the press service of the Ministry of Industry and Trade of the Russian Federation reported on April 18.

It is noted that clinical trials are conducted in accordance with the data from the Register of Permits for their conduct.

"Thus, it is at least premature to give an opinion on the effectiveness and safety of a medicinal product at this stage. It should be noted that this conclusion is also not (and cannot be) considered by the court," the ministry said in a statement.

The Ministry of Industry and Trade clarified that Lina M signed a state contract for the implementation of scientific research and development (R&D) in 2014 for the transfer of technology of foreign development.

"Even if the drug were registered, it would be neither original nor innovative. However, he certainly could have become socially significant. The work under the contract was supposed to be completed in 2017, but as of today they have not yet been completed," the press service said.

State of effects: a database of dangerous side effects of advanced cancer drugs has been created in the Russian Federation

How the new tool will help the development of personalized cancer therapy

On April 17, it became known from the materials of the case of the Moscow 9th Arbitration Court of Appeal, which considered the dispute between the Ministry of Industry and Trade of the Russian Federation and a pharmaceutical developer, that Russia had created an oncology drug that had no analogues in the whole world. We are talking about the drug "Afotid", already used for the treatment of cancer. The documents noted that the drug promotes the treatment of cancer at any stage.